Indraprastha Medical Corporation Limited (INDRAMEDCO) AI Stock Analysis

• Market Cap: ₹52.42B
• Dividend Yield: 0.79%
• Average Volume (3M): 89.52K
• Price to Earnings (P/E): 30.8
• Beta (1Y): 1.32
• Revenue Growth: 6.80%
• EPS Growth: 21.31%
• Country: IN
• Employees: 2,977
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 1.10
• Shares Outstanding: 91,673,000
• 10 Day Avg. Volume: 14,191
• 30 Day Avg. Volume: 89,522
• PEG Ratio: 0.75
• Price to Book (P/B): 6.04
• Price to Sales (P/S): 2.66
• P/FCF Ratio: 29.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: ₹626.00 ▲(10.22% Upside)

Indraprastha Medical Corporation Limited's overall stock score is driven by strong financial performance and bullish technical indicators. However, the high P/E ratio and overbought RSI suggest caution, as the stock may be overvalued with potential for a near-term correction.

Indraprastha Medical Corporation Limited Business Overview & Revenue Model

Company Description

Indraprastha Medical Corporation Limited provides hospital services in India. It offers services primarily in the areas of anesthesiology, pediatric, elder care, genomic medicine, health check, sugar, bariatric and metabolic surgery, bone marrow transplant, cancer, cardiac and cardiology, dermatology, dietetics and clinical nutrition, emergency care, endovascular surgery, endocrinology/diabetes care, ENT, fetal medicine, gastroenterology and hepatology, laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, internal medicine, laboratory services, neonatology, nephrology, neurosciences, nuclear medicine, ophthalmology, orthopedic, pediatric urology and pediatric surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology/radio diagnosis, respiratory sleep medicine and critical care, rheumatology, robotic surgery, spine surgery, transfusion medicine, transplant, and urology and andrology. The company operates cosmetic and dental clinics. Indraprastha Medical Corporation Limited was incorporated in 1988 and is based in New Delhi, India.

How the Company Makes Money

Indraprastha Medical Corporation Limited generates revenue primarily through the provision of healthcare services. The company's key revenue streams include patient fees for consultations, medical treatments, and surgical procedures. Additionally, it earns income from diagnostic services, outpatient services, and emergency care. The company may also engage in partnerships with insurance providers to facilitate patient access to its services, thereby broadening its customer base and ensuring a steady stream of revenue. Furthermore, ancillary services such as pharmacy sales and laboratory tests contribute to the company's overall earnings.

Indraprastha Medical Corporation Limited Financial Statement Overview

Summary

Indraprastha Medical Corporation Limited exhibits strong financial health with consistent revenue growth and profitability. The balance sheet reflects low leverage and solid equity, although attention to cash management is advised due to recent declines in cash reserves. The financial statements indicate a well-managed company with potential for continued growth, albeit with a need for vigilant cash flow management.

Income Statement

Indraprastha Medical Corporation Limited has demonstrated strong revenue growth over the years, increasing from 5,960 million INR in 2021 to 13,563 million INR in 2025. The gross profit margin has improved significantly, indicating strong operational efficiency, and the net profit margin has also shown consistent improvement, reaching 11.87% in 2025. The EBIT and EBITDA margins reflect healthy profitability, contributing to a robust income statement performance.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio consistently low, indicating low leverage risk. Return on equity has improved, reflecting efficient use of equity capital. The equity ratio is strong, showing financial stability; however, the decrease in cash and cash equivalents from 2024 to 2025 indicates potential liquidity considerations.

Cash Flow

The cash flow statements reveal stable operational cash flows, though there was a decline in free cash flow in 2025 compared to the previous year. The free cash flow to net income ratio is healthy, suggesting effective cash generation relative to profit. However, the decline in operating cash flow in 2025 needs monitoring to ensure continued liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.74B	13.56B	12.45B	10.99B	8.88B	6.13B
Gross Profit	3.69B	3.50B	3.13B	6.25B	4.79B	3.47B
EBITDA	2.69B	2.44B	2.07B	1.61B	1.17B	409.48M
Net Income	1.68B	1.61B	1.24B	861.50M	586.20M	23.30M
Balance Sheet
Total Assets	0.00	8.52B	7.23B	5.55B	4.62B	4.32B
Cash, Cash Equivalents and Short-Term Investments	3.22B	3.19B	2.24B	1.36B	660.10M	296.10M
Total Debt	0.00	327.60M	339.50M	24.80M	53.10M	78.18M
Total Liabilities	-5.97B	2.55B	2.45B	1.76B	1.36B	1.59B
Stockholders Equity	5.97B	5.97B	4.78B	3.79B	3.25B	2.73B
Cash Flow
Free Cash Flow	0.00	1.20B	1.31B	998.90M	418.10M	69.35M
Operating Cash Flow	0.00	1.57B	2.00B	1.44B	712.90M	278.98M
Investing Cash Flow	0.00	-1.11B	-1.58B	-1.08B	-511.00M	-201.62M
Financing Cash Flow	0.00	-458.80M	-323.80M	-260.40M	-33.70M	-31.47M

Indraprastha Medical Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 567.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDRAMEDCO, the sentiment is Positive. The current price of 567.95 is above the 20-day moving average (MA) of 541.28, above the 50-day MA of 495.37, and above the 200-day MA of 441.38, indicating a bullish trend. The MACD of 21.95 indicates Positive momentum. The RSI at 65.08 is Neutral, neither overbought nor oversold. The STOCH value of 67.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INDRAMEDCO.

Indraprastha Medical Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFIZER	―	₹243.86B	30.33	―	0.66%	4.35%	32.89%
INDRAMEDCO	―	₹52.42B	30.82	―	0.79%	6.80%	21.31%
GLAXO	―	₹465.11B	48.87	―	2.04%	6.65%	48.47%
CONCORDBIO	―	₹160.40B	45.04	―	0.75%	14.49%	13.70%
METROPOLIS	―	₹98.98B	64.71	―	―	12.86%	10.42%
BIOCON	―	₹498.48B	114.16	―	0.13%	6.80%	-75.66%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%